Oct 20, 2025 07:42AM
Oct 20, 2025 07:40AM
Aug 13, 2025 07:30AM
Aug 4, 2025 04:00PM
Aug 4, 2025 04:00PM
May 13, 2025 07:30AM
Jan 13, 2025 08:04AM Adaptimmune Therapeutics (ADAP) Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel
Jan 13, 2025 08:00AM
Dec 2, 2024 04:00PM
Nov 13, 2024 04:05PM
Aug 29, 2024 09:51AM
Aug 12, 2024 07:00AM
Aug 1, 2024 08:27PM
Aug 1, 2024 08:20PM Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Jul 19, 2024 01:41PM
May 16, 2024 02:45PM
May 15, 2024 07:30AM
Mar 27, 2024 07:30PM
Mar 6, 2024 07:00AM
Feb 27, 2024 08:05AM
Feb 27, 2024 08:00AM Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Jan 31, 2024 04:46PM
Jan 31, 2024 04:44PM
Jan 4, 2024 07:40AM
Jan 4, 2024 07:37AM
Dec 6, 2023 07:00AM
Nov 8, 2023 07:30AM
Oct 31, 2023 08:00AM Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Oct 23, 2023 04:15AM
Aug 9, 2023 07:29AM
May 25, 2023 05:03PM
May 25, 2023 05:00PM
May 16, 2023 07:00AM
May 12, 2023 07:29AM
Mar 6, 2023 06:33AM Adaptimmune Therapeutics (ADAP) Reports Q4, Provides Business Update
Mar 6, 2023 06:30AM
Mar 6, 2023 06:01AM
Mar 6, 2023 06:00AM
Mar 6, 2023 06:00AM
Mar 6, 2023 06:00AM
Jan 9, 2023 08:16AM
Jan 9, 2023 08:00AM Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Dec 23, 2022 01:20PM
Nov 8, 2022 07:30AM
Nov 8, 2022 07:03AM
Nov 8, 2022 07:00AM
Aug 4, 2022 07:30AM
Jun 15, 2022 07:00AM
May 26, 2022 05:00PM Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
May 9, 2022 07:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All